SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Ronald Reagan — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientRonald Reagan
Date of birth1911-02-06
IdentifiersMRN HR-ML008-SYN-TD; SSN (made up) 000-08-6047
Document date2001-04-14
AuthorMargaret Ellison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month post-fracture review with bone density testing and zoledronic acid. [S]

History of Present Illness

Mr. Reagan returns three months after the repair of his right hip fracture. He now walks in the house and out to the garden with his walker and supervision, and enjoys sitting outside. His hip no longer hurts, even after walking, and he has had no falls. Home physical therapy continues twice a week. His caregivers give cholecalciferol every day and report no missed doses of it or of donepezil. The evening restlessness is mild and unchanged, and the evening routine still settles it. His appetite is good, and he has gained 1 kg. [S]

ElementDetail
Interval changeWalking in the house and garden with a walker and supervision; no hip pain
FallsNone
MedicinesDonepezil and cholecalciferol taken daily; acetaminophen no longer needed
BehaviorMild evening restlessness, unchanged
FunctionBarthel Index 75, up from 55 at the first visit

Review of Systems

SystemResultFinding
ConstitutionalNegativeAppetite good; weight up 1 kg; no fever
CardiovascularNegativeNo lightheadedness on standing or fainting
GastrointestinalNegativeNo heartburn, nausea, or trouble swallowing
MusculoskeletalNegativeNo hip pain; no back pain
NeurologicalPositiveKnown memory loss, unchanged
PsychiatricPositiveMild evening restlessness; no low mood; GDS-15 score 3

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Donepezil 10 mg oral tablet, one tablet by mouth daily in the morningOne tablet by mouth daily in the morningOral route1997-03-07activeS
Acetaminophen 500 mg oral tablet, two tablets (1,000 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2001-01-14 to 2001-04-14completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every six hours as needed for severe painOne tablet by mouth every six hours as needed for severe painOral route2001-01-14 to 2001-02-10stoppedS
Diphenhydramine 25 mg oral capsule, one capsule by mouth at bedtimeOne capsule by mouth at bedtimeOral route2001-01-16 to 2001-02-10stoppedS
Enoxaparin 40 mg/0.4 mL prefilled syringe, inject 40 mg under the skin daily through day 35 after surgeryInject 40 mg under the skin once dailySubcutaneous route2001-01-14 to 2001-02-17completedS
Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2001-02-10activeS
Zoledronic acid 5 mg/100 mL intravenous infusion over at least 15 minutes, once yearly5 mg intravenously over at least 15 minutes once a year; first dose givenIntravenous route2001-04-14 to 2001-04-14completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2001-04-14Body height185cmS
2001-04-14Body weight77.5kgS
2001-04-14Body mass index (BMI) [Ratio]22.6kg/m2S
2001-04-14Systolic blood pressure130mm[Hg]S
2001-04-14Diastolic blood pressure72mm[Hg]S
2001-04-14Heart rate64/minS
2001-04-14Respiratory rate16/minS
2001-04-14Body temperature36.6CelS
2001-04-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-04-14Hemoglobin [Mass/volume] in Blood13.4g/dL13.2-16.6 g/dLNormalS
2001-04-14Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2001-04-14Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2001-04-14Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
2001-04-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2001-04-14Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2001-04-14Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2001-04-1425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2001-04-14Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma112U/L40-129 U/LNormalS
2001-04-14DXA Hip - left [Mass/Area] Bone density0.637g/cm2>=0.896 g/cm2LowS
2001-04-14Total score Barthel Index75{score}S
2001-04-14Geriatric depression scale (GDS) short version total3{score}S

Physical Exam

Vital signs recorded on 2001-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, pleasant, and well groomed
CardiovascularRegular rhythm at 64 per minute; no edema; no fall in blood pressure on standing, without symptoms
MusculoskeletalRight hip incision well healed; painless hip movement; no spinal tenderness; walks with the walker and supervision, steadier than at the last visit
NeurologicalOriented to person, not to date; no focal weakness

Problems

ProblemClinical statusVerificationCodeProvenance
Alzheimer's disease with late onset, disclosed in 1969activeconfirmed G30.1S — Synthetic modern coding of the publicly disclosed diagnosis.
Dementia due to Alzheimer's disease, moderate (FAST stage 5), with evening restlessnessactiveconfirmed F02.B0S — Synthetic stage; his actual stage at this age was not made public.
Osteoporosis with right hip fragility fracture after a fall at home, repaired with internal fixation; subsequent careactiveconfirmed M80.051DS — Synthetic modern coding of the documented January 2001 hip fracture as an osteoporotic fracture; bone density and fracture pattern are synthetic.
Vitamin D deficiencyresolvedconfirmed E55.9S — Synthetic finding from the first-visit 25-hydroxyvitamin D; repleted by three months.
Acute blood loss anemia after hip surgeryresolvedconfirmed D62S — Synthetic postoperative finding; resolved by three months.
History of fallingactiveconfirmed Z91.81S — Synthetic modern coding linked to the documented fall.
Personal history of colon cancer, operated on in 1960activeconfirmed Z85.038S — Synthetic modern coding of the documented 1985 operation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySerum calcium and kidney function before zoledronic acidBefore each intravenous doseCompleted todayCalcium 9.3 mg/dL; creatinine 1.08 mg/dL, eGFR 63, creatinine clearance about 50 mL/min, above the 35 mL/min limit
Laboratory25-hydroxyvitamin D and alkaline phosphatase after repletionRepeat after repletion, then yearlyCompleted todayVitamin D 36 ng/mL, up from 16; alkaline phosphatase back to normal at 112 U/L
LaboratoryHemoglobinFollow-up of postoperative anemiaCompleted today13.4 g/dL, up from 11.1
LaboratoryPhosphorus and 24-hour urine calciumOnce, in the secondary-causes workup before treatmentDeferredNot obtained before today's infusion, a deviation from the protocol. Serum calcium, PTH, and alkaline phosphatase point to vitamin D deficiency as the only secondary cause, so a missed cause that would change treatment is unlikely. Phosphorus will be added to the tests before the second infusion; a 24-hour urine collection only if bone density falls on treatment
LaboratoryBone turnover markers (CTX or P1NP)Baseline and 3 to 6 months after starting therapyNot indicatedAn infusion given in clinic makes adherence certain, and BHOF treats the markers as optional
ImagingDXA of the hip and spineBaseline after the fracture; every 1 to 3 years on therapyCompleted todayLeft total hip T-score -2.8 (0.637 g/cm²); lumbar spine T-score -1.9
ImagingVertebral fracture assessmentAt baseline after a low-trauma fracture or with a T-score of -2.5 or lowerDeferredNot done with today's DXA although both triggers apply, a deviation from the protocol. Treatment is already indicated by the hip fracture, so the decision is unchanged; he has no back pain and no height loss. Add it to the next DXA, sooner if back pain or height loss appears
SurveyFRAX 10-year fracture riskAfter the fracture and with each DXADeferredNot calculated with today's DXA, a deviation from the protocol. The hip fracture already establishes the need for treatment, so the decision is unaffected; calculate it with the next DXA
Medication safetyAntiresorptive therapy after the fracturePromptly, within months of the fractureCompleted todayZoledronic acid 5 mg given today, three months after the repair, once vitamin D was repleted
ExaminationStanding heightYearlyCompleted today185 cm, unchanged
ExaminationPain assessmentEvery visitCompleted todayNo hip pain; scheduled acetaminophen stopped
ExaminationPhysical and occupational therapy progressEvery visitCompleted todayBarthel Index 75, up from 55; walking goal met
ExaminationCDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressureEvery primary care visit after the fractureCompleted todayNo falls; steadier with the walker; no fall in blood pressure on standing
ExaminationTimed Up and GoWhen home therapy ends, then yearly or with a changeDuePlanned when home therapy ends, by the six-month review
ExaminationHip radiographsOnly for pain, loss of function, or suspected nonunionNot indicatedNo pain and steady progress
ExaminationHome safety evaluationAt diagnosis and each follow-upCompleted todayChanges from the home safety assessment still in place
Medication safetyAGS Beers Criteria medication reviewEvery visit and at each transition of careCompleted todayAcetaminophen stopped; no Beers-listed medicine
Medication safetyCholinesterase inhibitor benefit and tolerabilityEach follow-upCompleted todayHeart rate 64; no fainting; continue
SurveyNeuropsychiatric symptom screen (NPI-Q)Every visitCompleted todayMild evening restlessness, unchanged; no hallucinations or aggression
SurveyDepression screen (GDS-15)At 1, 3, and 6 months after the fracture; yearly in dementiaCompleted todayScore 3, below the threshold of 5
SurveyCognitive test (MoCA), FAST stage, and ADL and IADL scoresAt diagnosis, then yearlyUp to dateDone at the first visit and confirmed by neurology; next in about ten months
SurveyCaregiver assessment with the Zarit Burden InterviewAt diagnosis, then every 6 to 12 monthsUp to dateRepeat at the six-month review
Self-managementAdvance care planningAt diagnosis, yearly, and at stage changesCompleted todayPOLST form completed
Self-managementCalcium intake from food and supplementsOngoing; target 1,000 to 1,200 mg a dayCompleted todayCalcium-rich food at each meal; no calcium tablet needed

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021); The clinician's guide to prevention and treatment of osteoporosis (2022); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026)

Follow-up: Six-month post-fracture, dementia, and caregiver review in three months, with calcium and hemoglobin. Next scheduled visit 2001-07-14: six-month post-fracture, dementia, and caregiver review. [S]